



# AS3DVIEW

**Addressing the Most Common Cancer:  
The Pathology, Epidemiology, and Treatment Options of  
ADVANCED and METASTATIC BCC**

**THURSDAY, MAY 6, 2021**



*This activity is provided by Med Learning Group.*

*This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM) and AMEDCO.*

*This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.*



# A3DVIEW | Addressing the Most Common Cancer:

The Pathology, Epidemiology, and Treatment Options of ADVANCED and METASTATIC BCC

## Agenda

- Basal Cell Carcinoma: Introduction
  - Epidemiology/statistics
  - Prognostic factors
- Staging and Guidelines
  - Considerations for aggressive BCC
- BCC Failing or Not Amenable to Surgery or Radiation
  - Sonic hedgehog pathway
    - Vismodegib and sonidegib
  - Hedgehog side effects
  - Alternate dosing regimens
  - When disease progresses on hedgehog inhibition
    - Immunotherapy: the cancer/immunity cycle
    - Immune checkpoints and checkpoint inhibitors
      - Cemiplimab
      - Pembrolizumab and other investigational agents
- Case Study Presentations and Conclusions
- Q&A

***A 3D View: Addressing the Most Common Cancer: The Pathology, Epidemiology,  
and Treatment Options of Advanced and Metastatic BCC***

**FACULTY**

**Anna Bar, MD**

Associate Professor of Dermatology  
Co-director of Mohs Micrographic Surgery  
Oregon Health & Science University (OHSU)  
Portland, OR

**Justin Leitenberger, MD**

Assistant Professor of Dermatology  
Co-director of Mohs Micrographic Surgery  
Oregon Health & Science University (OHSU)  
Portland, OR

**PROGRAM OVERVIEW**

This case-based virtual activity will focus on treatment and management of patients with advanced/metastatic basal cell skin cancer.

**TARGET AUDIENCE**

This activity is designed to meet the educational needs of Mohs surgeons, onco-dermatologists, medical oncologists, dermatologists and other healthcare practitioners who care for patients with advanced/metastatic basal cell skin cancer.

**LEARNING OBJECTIVES**

On completing of the program, attendees should be able to:

- Discuss the pathogenic drivers of BCC including cellular signaling pathways and immune dysfunction
- Review the utility of Mohs micrographic surgery in the evaluation and therapeutic intervention in BCC
- Describe systemic therapeutic approaches in the treatment of locally advanced and metastatic BCC
- Summarize the clinical trial data for emerging immunotherapy agents for advanced or metastatic basal cell skin cancer

**ACCREDITATION STATEMENT:** Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**CREDIT DESIGNATION STATEMENT:** Med Learning Group designates this live virtual activity for a maximum of 1.0 *AMA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

**CNE ACCREDITATION STATEMENT:** Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

**NURSING CREDIT INFORMATION:**

Purpose: This program would be beneficial for nurses involved in the care of patients with advanced/metastatic basal cell skin cancer. Credits: 1.0 ANCC Contact Hour.

**Accreditation Statement**



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Pharmacists and Pharmacy Technicians**

Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.

**NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.**

**DISCLOSURE POLICY STATEMENT**

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

**DISCLOSURE OF FINANCIAL RELATIONSHIPS**

**Anna Bar, MD** receives consulting fees from Castle and Regeneron Pharmaceuticals. She received research funding to her institution from Castle, Pelle Pharm, and Polynoma.

**Justin Leitenberger, MD** has nothing to disclose.

### **CME Content Review**

The content of this activity was independently peer reviewed.  
The reviewer of this activity has nothing to disclose.

### **CNE Content Review**

The content of this activity was peer reviewed by a nurse reviewer.  
The reviewer of this activity has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

### **Staff, Planners and Managers**

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.

Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.

Chris Drury, Medical Director for Med Learning Group, has nothing to disclose.

Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.

Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group, has nothing to disclose.

Brianna Hanson, Outcomes and Accreditation Coordinator for Med Learning Group, has nothing to disclose.

## **DISCLOSURE OF UNLABELED USE**

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

## **METHOD OF PARTICIPATION**

There are no fees for participating and receiving CME/CNE credit for this live virtual activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures.
2. Participate in the live virtual activity.
3. Submit the evaluation form to the Med Learning Group.

You will receive your certificate as a downloadable file.

## DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [info@medlearninggroup.com](mailto:info@medlearninggroup.com)

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at [www.medlearninggroup.com/privacy-policy/](http://www.medlearninggroup.com/privacy-policy/)

## AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [info@medlearninggroup.com](mailto:info@medlearninggroup.com)



Provided by Med Learning Group



This activity is co-provided by Ultimate Medical Academy/CCM and AMEDCO.

This activity is supported by an independent medical education grant from  
Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

## Live Learner Notification

### Med Learning Group

**A 3D View: Addressing the Most Common Cancer: The Pathology, Epidemiology, and Treatment Options of Advanced and Metastatic BCC**

May 6, 2021

Online

### Acknowledgement of Financial Commercial Support

Regeneron

### Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

### Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. You must attend the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

### Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Pharmacists and Pharmacy Technicians

Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.

UAN(s): JA4008163-9999-21-074-L04-P / JA4008163-9999-21-074-L04-T

**NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.**

### Objectives - After Attending This Program You Should Be Able To

1. Discuss the pathogenic drivers of BCC including cellular signaling pathways and immune dysfunction.
2. Review the utility of Mohs micrographic surgery in the evaluation and therapeutic intervention in BCC.
3. Describe systemic therapeutic approaches in the treatment of locally advanced and metastatic BCC.

### Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1--6.2, 6.5). All individuals in a position to control the content of CE are listed below:

Name	Relationship: Commercial Interest
Anna Bar	Consulting Fees: Regeneron Pharmaceuticals; Research Funding: Castle, Mavis, Pelle Pharm
Felecia Beachum	NA
Chris Drury	NA
Matthew Frese	NA
Christina Gallo	NA
Brianna Hanson	NA
Justin Leitenberger	NA
Scott McGee-Plys	NA
Lauren Welch	NA

### How to Get Your Certificate

1. Go to <http://mlg.cmecertificateonline.com>
2. Click on "5.6.21 A 3D View: Addressing the Most Common Cancer: The Pathology, Epidemiology, and Treatment Options of Advanced and Metastatic BCC" link.
3. Complete the post-test, click the provided link to go to the online evaluation site.
4. Evaluate the meeting, click the provided link to open your credit certificate.

5. Print/save all pages of your certificate for your records.

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)







